Y-320
目录号 : GC13066
An inhibitor of IL-15-mediated CD4 T cell activation
Cas No.:288250-47-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Y-320 is a new phenylpyrazoleanilide immunomodulator [1].
Immunotherapy refers to treatment of disease by suppressing, inducing or enhancing an immune response.
Y-320 is a new phenylpyrazoleanilide immunomodulator. Y-320 inhibited IL-17 production by CD4 T cells induced by IL-15 with IC50 values of 20-60 nM [1].
In type II collagen-induced arthritis (CIA) mice, oral administration of Y-320 (0.3-3 mg/kg) reduced IL-17 mRNA expression and significantly inhibited the development of joint destruction and arthritis. The combination of Y-320 with anti-murine tumor necrosis factor-α (TNF-α) monoclonal antibody exhibited a synergistic effect. In cynomolgus monkeys, Y-320 (0.3-1 mg/kg) relieved CIA. These results suggested that Y-320 could be a useful candidate for therapy of rheumatoid arthritis (RA) [1].
Reference:
[1]. Ushio H, Ishibuchi S, Oshita K, et al. A new phenylpyrazoleanilide, y-320, inhibits interleukin 17 production and ameliorates collagen-induced arthritis in mice and cynomolgus monkeys. Pharmaceuticals (Basel), 2013, 7(1): 1-17.
| Cas No. | 288250-47-5 | SDF | |
| 化学名 | 1-(4-chlorophenyl)-N-[3-cyano-4-(4-morpholin-4-ylpiperidin-1-yl)phenyl]-5-methylpyrazole-4-carboxamide | ||
| Canonical SMILES | CC1=C(C=NN1C2=CC=C(C=C2)Cl)C(=O)NC3=CC(=C(C=C3)N4CCC(CC4)N5CCOCC5)C#N | ||
| 分子式 | C27H29ClN6O2 | 分子量 | 505.01 |
| 溶解度 | ≥ 24.8mg/mL in DMSO with gentle warming | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.9802 mL | 9.9008 mL | 19.8016 mL |
| 5 mM | 0.396 mL | 1.9802 mL | 3.9603 mL |
| 10 mM | 0.198 mL | 0.9901 mL | 1.9802 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。